Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (748)	3/27/1998 4:29:00 PM
From: James Baker	Read Replies (1) \| Respond to of 9523

BigK, Our old friend Dr Barata resurfaces with some cautionary comments from Reuters: *<<<<<<Barada warned that not all men would be helped by Viagra. ''Any type of therapy that you have, particularly those oral therapies, help those most that need it the least,'' he said. ''The closer they are to being considered 'normal' the better response they are going to have.'' But he said knowing about the pill would get men into their doctors' offices to talk about their problems. As many as 30 million American men have varying degrees of erectile dysfunction. In 21 trials of 4,500 men, 59 percent said Viagra helped them for impotence with physiological causes of dysfunction. Eighty-one percent of men with psychological impotence were helped. Side-effects included headache, flushing and nausea. Men taking nitroglycerin should not use Viagra. ''The incidence (of side-effects) was about 20-30 percent, but few of the men dropped out,'' said Barada, who tested Viagra. ''If you have a side-effect you have to decide the benefit's worth it.''>>>>>>>>> When you are participating in a study and being monitored and "expected to produce" (data if nothing else) patients are less likely to drop out. What will 20-30% mean in the real world? Jim